The Microcyn® Technology platform
was first introduced in Mexico in 2003. The Mexican
Ministry of Health approved Microcyn® as
a disinfectant and antiseptic in July of that same
year, and then as a sterilant in November.
Many key medical opinion leaders
in Mexico and Europe have tested and validated the
efficacy and safety. It has received CE mark approval
in Europe for treatment of acute and chronic wounds as
well as two United States FDA 510K clearances to moisten,
lubricate, cleanse and debride wounds and burns.
Microcyn® Technology is
initially being used in the treatment of complex
wounds, such as burns and diabetic
foot ulcers, in which infection can pose significant
danger to the patient. While in-vitro studies have
shown that Microcyn® can
effectively eradicate bacteria, numerous in-vivo studies
have also confirmed the same bacteria-eradicating
results in open wounds. In numerous third-party
case studies conducted to date by individual physicians,
the use of both systemic and dermal antibiotics has
been significantly reduced when Microcyn® Technology
was used. The results of a 64-patient study in burn
patients were presented at the Texas Surgical Society
in April 2005.
and third-degree burns are very challenging
due to the high risk of infection since the skin
is no longer a barrier to infection. As well, skin
grafts offer potential for a number of complications.
"takes" or is successful when new blood vessels
and tissue form in the injured area. Sometimes, skin
grafts do not take because of early complications such
as infection, which is the most common cause of graft
failure. Based upon the results from a clinical study
conducted at the Guadalajara Civil
Hospital, when patients are treated with Microcyn® Technology in
a comprehensive treatment program, healing
of the burns is accelerated, the levels
of pain and infection
reduced and the patient hospital stay is significantly
ulcers oftentimes present a devastating
lifestyle. The pain is constant and the odor horrific.
These patients live with both the pain and decaying
stench 24 hours a day, seven days a week—many
for the greater part of their lives. The degree
of ulceration is oftentimes exacerbated by a general
neglect of the wound that can be the result of
limited access to modern medical care.
Compounding this is the fact that
invading bacteria can grow resistant in reaction to
antibiotics that are used to treat the ulcer. Conventional
antiseptics provide some relief against most bacteria.
However, many antiseptics can actually induce damage
to the healthy tissue surrounding these ulcers. It
is a real dilemma since what is typically used in an
attempt to prevent infection may end up causing even
greater harm to the patient.
Within a few weeks after first treating
patients with the Microcyn® Technology regimen,
physicians begin to see healing in decades-old ulcers
that was previously unheard of. The photos below graphically
illustrate the significant results achieved on these
ulcers when treated with a Microcyn® Technology-based
Microcyn® does not have U.S. FDA clearance for
claims other than to moisten, lubricate, cleanse
and debride wounds.